Ogivri

Active Ingredient(s): Trastuzumab-dkst
FDA Approved: * December 1, 2017
Pharm Company: * MYLAN GMBH
Category: Cancer

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.[3][4][5][6] It is specifically used for cancer that is HER2 receptor positive.[3] It may be used by itself or together with other chemotherapy medication.[3] Trastuzumab is given by slow injection into a vein and injection just under the skin.[3]&am... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ogivri 420 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 67457-845
Labeler:
Mylan Institutional LLC
OgivriOgivri Kit
NDC: 67457-847
Labeler:
Mylan Institutional LLC
Ogivri 150 mg/7.4ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 67457-991
Labeler:
Mylan Institutional LLC
Ogivri 150 mg/7.4ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 83257-001
Labeler:
Biocon Biologics Inc.
Ogivri 420 mg/20ml Intravenous Injection, Powder, Lyophilized, for Solution
NDC: 83257-003
Labeler:
Biocon Biologics Inc.
OgivriOgivri Kit
NDC: 83257-004
Labeler:
Biocon Biologics Inc.

Related Brands

Drugs with the same active ingredients